Accession Number:



Integrated Genomic Biomarkers to Identify Aggressive Disease in African Americans with Prostate Cancer

Descriptive Note:

Technical Report,01 Sep 2015,31 Aug 2016

Corporate Author:

Henry Ford Health System Detroit United States

Personal Author(s):

Report Date:


Pagination or Media Count:



The purpose of our research is to identify somatic copy number alterations and methylation markers in the primary tumors of African American AA men that can serve as a component of their recurrence risk assessment and be applied in treatment planning in attempt to reduce the racially disparate rates of mortality from prostate cancer. Through whole genome copy number alteration and methylation scans, the study will identify individual and integrated DNA-based biomarkers of biochemical recurrence in 200 AA men 100 with and 100 without biochemical recurrence. These biomarkers will then be validated in an independent set of 200 AA men. In the first year of funding, we have enumerated both discovery and validation samples have obtained formalin fixed paraffin embedded blocks from 300 of these men have completed pathology review of 70 of the discovery sample tumors macrodissected and performed DNA extraction from 50 tumors, which will serve as a pilot sample of both the methylation and copy number platforms and completed the running and quality control of two tumors on the copy number assay. We have also started a manuscript exploring the effectiveness of a commonly used clinicopathologic predictor of prostate cancer in AA men and whether that effectiveness depends on genetic African ancestry, which is significant as we proposed that our genomic biomarkers would add to this established predictor.

Subject Categories:

  • Medicine and Medical Research
  • Genetic Engineering and Molecular Biology
  • Biochemistry

Distribution Statement: